Subtype
Thyroid Gland Neoplasm
CI-CAN-00001600Explore in graph →
Non-malignant189 active trials10 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001600Explore in graph →
Clinical trials
891 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04554680 | Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy | unknown | Phase 2 | 5 | National University Hospital, SingaporeOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT01270321 | Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer | completed | Phase 2 | 42 | Emory UniversityOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT03072160 | Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2021 | clinicaltrials |
| NCT00514046 | Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2020 | clinicaltrials |
| NCT02138214 | Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer | completed | Phase 2 | 117 | University of Wisconsin, MadisonOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04612894 | Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer | unknown | Phase 2 | 31 | Fudan UniversityOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04574817 | Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC) | unknown | Phase 2 | 66 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT00603941 | A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel | terminated | Phase 1 / Phase 2 | 19 | Daiichi SankyoINDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT04524884 | Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study | unknown | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT01728623 | A Study of E7080 in Subjects With Advanced Thyroid Cancer | completed | Phase 2 | 51 | Eisai Co., Ltd.INDUSTRY | 1 | Aug 14, 2020 | clinicaltrials |
| NCT00668811 | Sutent Adjunctive Treatment of Differentiated Thyroid Cancer(IIT Sutent) | completed | Phase 2 | 23 | Medstar Health Research InstituteOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT01788982 | Nintedanib(BIBF1120) in Thyroid Cancer | completed | Phase 2 | 100 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 31, 2020 | clinicaltrials |
| NCT02726503 | Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer(HOPE) | completed | Phase 2 | 39 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT00287287 | REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas | completed | Phase 2 | 25 | Kenneth AinOTHER | 1 | Jun 12, 2020 | clinicaltrials |
| NCT00784303 | Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology | completed | Phase 2 | 117 | Eisai Inc.INDUSTRY | 6 | Apr 22, 2020 | clinicaltrials |
| NCT03211117 | Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer | completed | Phase 2 | 3 | Mayo ClinicOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT00625846 | Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer | completed | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 5 | Feb 26, 2020 | clinicaltrials |
| NCT02614495 | Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma | completed | Phase 2 | 66 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02390739 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 16, 2019 | clinicaltrials |
| NCT00582712 | An Initial Study of Lithium in Patients With Medullary Thyroid Cancer | terminated | Phase 2 | 5 | University of Wisconsin, MadisonOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT01013597 | Trial of LBH589 in Metastatic Thyroid Cancer | completed | Phase 2 | 13 | University of Wisconsin, MadisonOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT00654238 | Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer | completed | Phase 2 | 59 | University of PennsylvaniaOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02084732 | Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study | completed | Phase 2 | 35 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 1 | Nov 13, 2019 | clinicaltrials |
| NCT02657369 | A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) | terminated | Phase 2 | 34 | Eisai Inc.INDUSTRY | 5 | Oct 15, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT02289144 | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT02390934 | Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer(RAD-THYR) | completed | Phase 2 | 13 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT02586350 | Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) | completed | Phase 2 / Phase 3 | 91 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 21, 2019 | clinicaltrials |
| NCT02472080 | Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study(THYGEMOX) | terminated | Phase 2 | 21 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 18, 2019 | clinicaltrials |
| NCT03002623 | CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer | terminated | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Dec 21, 2018 | clinicaltrials |
| NCT00104871 | Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT00085293 | Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT00923247 | A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) | terminated | Phase 1 / Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT00181168 | Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer | completed | Phase 2 | 63 | Johns Hopkins UniversityOTHER | 2 | Nov 2, 2018 | clinicaltrials |
| NCT00896454 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | completed | Phase 2 | 33 | AmgenINDUSTRY | 5 | Oct 17, 2018 | clinicaltrials |
| NCT00804830 | Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer | terminated | Phase 2 | 15 | Region SkaneOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT01025453 | Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer | completed | Phase 2 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 15, 2018 | clinicaltrials |
| NCT01502410 | Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 3 | Jun 26, 2018 | clinicaltrials |
| NCT02839655 | Prospective Study Assessing Thyroidectomy Using Robot(EVATAR) | unknown | Phase 2 | 17 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 15, 2018 | clinicaltrials |
| NCT01182285 | A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | May 16, 2018 | clinicaltrials |
| NCT00098345 | Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer | completed | Phase 2 | 40 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | May 7, 2018 | clinicaltrials |
| NCT01811212 | Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2018 | clinicaltrials |
| NCT00126568 | Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 19, 2018 | clinicaltrials |
| NCT03387943 | PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 3, 2018 | clinicaltrials |
| NCT01747512 | An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT) | withdrawn | Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 0 | Nov 14, 2017 | clinicaltrials |
| NCT03300765 | Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer | unknown | Phase 2 | 20 | Xiayun He, MDOTHER | 1 | Oct 3, 2017 | clinicaltrials |
| NCT02114658 | Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients | completed | Phase 2 | 18 | BayerINDUSTRY | 1 | Aug 3, 2017 | clinicaltrials |
| NCT03167385 | Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 30, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Mar 5, 2021source: clinicaltrials